From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study

from TheBrief.Health · host TheBrief.Health

This review examines 7-year CROWN trial data showing lorlatinib’s unprecedented durability in ALK-positive NSCLC, highlighting survival gains, CNS protection, resistance suppression, and toxicity management.

Episode metadata supplied by the publisher feed · Published Jun 9, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study

0:00 2:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 2 minutes long.

When was this TheBrief.Health episode published?

This episode was published on June 9, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!